Europe — EMA
Palonosetron Onkogen
Palonosetron, the active ingredient in Palonosetron Onkogen, is a 5-HT3 receptor antagonist presented as a 0.075 mg/1 ml solution for intravenous use.
Request sourcing
What is Palonosetron?
Palonosetron, the active ingredient in Palonosetron Onkogen, is a 5-HT3 receptor antagonist presented as a 0.075 mg/1 ml solution for intravenous use. It is employed to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients.
GNH USA supplies Palonosetron Onkogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.
What is Palonosetron used for?
Palonosetron is used in the management of nausea and vomiting related to chemotherapy and surgery. It helps: - Chemotherapy‑induced nausea and vomiting (CINV): Provides the most effective prevention of acute and delayed episodes of C‑ C … - Post‑operative Post‑operative … … - ...
What are the side effects of Palonosetron?
Common ...
What precautions apply to Palonosetron?
...
